Becton, Dickinson and BDX
Becton, Dickinson and Company (BDX) is a medical technology company that designs, manufactures, and sells medical devices, laboratory equipment, and diagnostic solutions for hospitals, laboratories, and healthcare settings worldwide. BDX shows strong momentum (8.17) and an attractive forward valuation (forward P/E 13.83), but its financial health is mediocre (ND/EBITDA 2.63, liquidity 0.86) and earnings growth is very negative (-31.4%), weighed down by SEC regulatory and litigation pressure.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Becton, Dickinson and Company (BDX) is a medical technology company that designs, manufactures, and sells medical devices, laboratory equipment, and diagnostic solutions for hospitals, laboratories, and healthcare settings worldwide. BDX shows strong momentum (8.17) and an attractive forward valuation (forward P/E 13.83), but its financial health is mediocre (ND/EBITDA 2.63, liquidity 0.86) and earnings growth is very negative (-31.4%), weighed down by SEC regulatory and litigation pressure.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.0 |
| Quality / Moat | 5.5 |
| Valuation | 6.1 |
| Growth | 2.7 |
| Dividend | 6.0 |
| Momentum | 8.2 |
| Risk & Context | 8.2 |
OVERALL SCORE: 5.8/10
Context and risks
BDX faces specific SEC regulatory and litigation pressure, a company-specific risk not captured by financial metrics. Additionally, its liquidity ratio of 0.86 indicates a tight short-term position that could amplify the impact of any sanction or settlement.
News considered in the analysis
- Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum — La integración de BD en Waters impulsa el momentum, pero el impacto en beneficios de BDX es indirecto y ya parcialmente descontado.
- How Far Can BSX Stock Swing After Losing More Than Half Its Value? — Noticia sobre Boston Scientific (BSX), competidor, sin información nueva sobre BDX.
- Why Is Becton Dickinson (BDX) Facing Fresh SEC And Litigation Pressure? — Presión regulatoria y de litigios de la SEC; riesgo material para la empresa, aunque el desenlace es incierto.
- Jim Cramer Said These 2 Stocks Were Sold Because Of A Rotation – But Is He Right? — Opinión de un analista sin información nueva sobre BDX.
- Why BSX Stock Lost More Than Half Its Value While Sales Kept Rising — Noticia sobre BSX, no relevante para BDX.
Verdict: Hold; the forward valuation is reasonable, but weak earnings and regulatory risk limit near-term upside.
Main risk: SEC regulatory and litigation pressure is the main specific risk for BDX, with a potentially material impact on its results and reputation.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →